Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Total Stockholders Equity : ¥1,567.0 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Total Stockholders Equity?

Suzhou Zelgen Biopharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was ¥1,567.0 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Suzhou Zelgen Biopharmaceuticals Co's Book Value per Share for the quarter that ended in Jun. 2024 was ¥5.92. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Suzhou Zelgen Biopharmaceuticals Co's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.61.

Suzhou Zelgen Biopharmaceuticals Co Total Stockholders Equity Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Total Stockholders Equity Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

3.43

1,617.73

1,196.32

759.12

1,632.85

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Stockholders Equity	Get a 7-Day Free Trial															1,817.62	1,732.14	1,632.85	1,593.69	1,567.04

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Suzhou Zelgen Biopharmaceuticals Co's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1567.044	-	0)	/	264.708
	=	5.92

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Suzhou Zelgen Biopharmaceuticals Co's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(927.384	+	29.18)	/	1567.044
	=	0.61

Suzhou Zelgen Biopharmaceuticals Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Zelgen Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN

Website

http://www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.

Executives

Zhang Bin	Core technical personnel
Huang Gang	senior management
Lv Bin Hua	Directors, senior managers, core technical personn
Lu Hui Ping	Directors, senior managers
Gao Qing Ping	senior management
Wu Ji Sheng	Directors, senior managers, core technical personn
Zhang Jun Li	senior management
Wu Li Qing	Core technical personnel
	Core technical personnel
Sheng Ze Lin	Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co Headlines

No Headlines